Delivery of Radiation at the Lowest Dose Rate by a Modern Linear Accelerator is Most Effective in Inhibiting Prostate Cancer Growth

Keren Tazat, PhD¹, Oleg Reshetnyak, MD¹, Natan Shtraus, MSc²,³, Ifat Sayag, MSc¹, Nicola J. Mabjeesh, MD, PhD¹,⁴, and Sharon Amir, PhD¹

Abstract
Purpose: External beam radiotherapy is one of the treatment options for organ-confined prostate cancer. A total dose of 70 to 81 Gray (Gy) is given daily (1.8-2.5 Gy/d), with a dose rate of 3 to 6 Gy/min over 28 to 45 treatments during 8 to 9 weeks. We applied the latest technological development in linear accelerators for enabling a wide range of dose rates (from 0.2-21 Gy/min) to test the effect of different delivery dose rates on prostate tumor growth in an animal xenograft model.

Materials and Methods: A prostate cancer xenograft model was established in CD1/nude mice by means of PC-3 and CL-1 cells. The animals were radiated by a TrueBeam linear accelerator that delivered 4 dose rates ranging from 0.6 to 14 Gy/min, and reaching a total dose of 20 Gy. The mice were weighed and monitored for tumor development twice weekly. A 2-way analysis of variance was used to compare statistical differences between the groups.

Results: Tumor growth was inhibited by radiation at all 4 dose rates in the 20 study mice compared to no radiation (n = 5, controls). The most significant reduction in tumor volumes was observed when the same dose of radiation was delivered at a rate of 0.6 Gy/min (P < .01). The animals’ weights were not affected by any dose rate.

Conclusions: Delivery of radiation with a TrueBeam linear accelerator at the lowest possible rate was most effective in prostate cancer growth inhibition and might be considered a preferential treatment mode for localized prostate cancer.

Keywords
radiation, dose rate, prostate cancer, xenograft model, linear accelerator

Introduction
Prostate cancer is the second leading cause of cancer-related deaths among American men following heart disease (CDC, C.f.D.C.a.P. Cancer among men. 2015; Available from: https://gis.cdc.gov/cancer/USCS/DataViz.html).¹ The majority of patients are diagnosed with localized prostate cancer and successfully treated with radical prostatectomy or radiation therapy. Radiotherapy usually involves external beam radiotherapy or brachytherapy,² and photons are the main particles used in the external radiotherapy approach.³ Recent breakthrough technology of external beam radiation, such as linear accelerators, can produce higher levels of energy and precision delivery of radiation to the tumors at a high delivery rate, while minimizing the damage to the surrounding tissues, reduce costs, and improve patient convenience.³ These high-precision photon radiotherapies have improved treatment outcomes in various malignancies, including prostate cancer.³

¹ Prostate Cancer Research Laboratory, Tel Aviv University, Tel Aviv, Israel
² Institute of Radiotherapy, Tel Aviv Medical Center, Tel Aviv, Israel
³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁴ Department of Urology, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Corresponding Author:
Sharon Amir, Prostate Cancer Research Laboratory, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 6423910, Israel.
Email: sharonami@tlvmc.gov.il
A wide range of dose rates has been used in radiotherapy, extending from a few Gray (Gy) per day to tens of Gy in a small fraction of a second. For localized prostate cancer, daily small doses (1.8-2 Gy) of radiation at a rate of 4 Gy/min over 8 to 9 weeks have traditionally been delivered, with the total dose ranging between 70 and 81 Gy over 38 to 45 treatments. A predefined radiation dose can be delivered by employing variable time spans and modulating dose rates. The impact of dose rate on the extent of radiation-induced biological effects in cells has been studied in depth. Those studies showed that small dose rates are more effective in inducing genetic damage and cell death compared to high dose rates for the same magnitude of radiation dose. However, the issue of the impact of different delivery dose rates on tumor growth, particularly in prostate cancer, is still unresolved. The feasibility of delivering a wide range of dose rates by means of modern linear accelerators allowed us to study the effect of different delivery rates of the same dose on tumor growth in a prostate cancer xenograft model.

Materials and Methods

Cell Culture

Both PC-3 and CL-1 human prostate cancer cells were purchased from American Type Culture Collection. The cells were cultured in RPMI-1640 containing 10% fetal bovine serum and antibiotics, and incubated in a 5% CO₂ humidified incubator at 37 °C.

Animal Studies

The animal procedures were carried out under institutional guidelines of the Tel Aviv Sourasky Medical Center (permission number 11-6-17). PC-3 and CL-1 cells were suspended in an equal volume of phosphate buffered solution and matrigel and kept on ice to prevent cell culturing. A total of $0.5 \times 10^6$ of PC-3 or $1 \times 10^6$ of CL-1 cells were injected subcutaneously by means of a 23G syringe needle into the right hind quarters of CD1/nude mice. When the tumor volume reached 100 mm³, the mice were randomized into 5 groups for each xenograft model (n = 5 per group) as follows: (1) no treatment (controls), (2) to (5) radiation treatment for a total dose of 2 Gy/d in dose rates of 0.6 Gy/min, 2 Gy/min, 4 Gy/min, and 14 Gy/min, respectively. Groups 2 to 5 were radiated with 2 Gy daily $\times 5$ days/week for 2 weeks, yielding a total dose of 20 Gy. The no-radiation control group underwent the same handling without receiving radiation. Metal identification tags were attached to the animals’ ears in order to distinguish among them. The mice were weighed and monitored for tumor development twice weekly. Tumor variables were measured with calipers, and tumor volume was calculated by width$^2 \times$ length $\times 0.5$, which is an estimate derived from the formula for obtaining sphere volume. The mice were sacrificed by CO₂ inhalation one week after the last session of radiation.

Radiation

Radiation was carried out in a TrueBeam linear accelerator (Varian Medical System) with X-ray energy outputs of 6 MV and dose rates of 0.6 Gy/min, 2 Gy/min, 4 Gy/min, and 14 Gy/min. The mice were secured in plastic holders, and the collimated X-ray beam radiated an area of $24 \times 24$ mm² at the tumor site, which was large enough to cover the entire area of the largest tumor.

Statistical Analysis

The statistical analysis of the results was performed with a 2-way analysis of variance (ANOVA) test. The results were reported as mean ± SE as indicated in the figures. Data were considered significant when $P \leq .05$.

Results

Effect of Delivery of Radiation at Each Dose Rate on Prostate Tumor Growth

We established a xenograft model of CD1/nude mice in order to study the effect of 4 radiation dose rates on prostate cancer tumor growth. Following the implantation of prostate cancer cells (PC-3 and CL-1), the mice were divided into 5 groups (4 different dose rates and 1 control as specified in the Material and Method section) when the tumor volume had reached 100 mm³. The study mice underwent radiotherapy 5 days a week for 2 weeks, thus receiving a total dose of radiation of 20 Gy. As expected, tumors that were not radiated exhibited significantly increased tumor volume compared with tumors that were treated with any rate of radiation (Figures 1A and 2A for PC-3 and CL-1 cells, respectively). Moreover, the lower the dose rate of radiation treatment, the stronger the inhibition of the tumor growth, especially in tumors that were formed by PC-3 cells (Figure 1B). The significance of the differences between the groups is depicted in Table 1. CL-1 tumors had similar radiation responses compared to PC-3 tumors; however, the differences in tumor growth inhibition at the lower doses were less significant (Figure 2B and Table 2). Of note, the CL-1 tumors exhibited a more prolonged radiation response at the lowest radiation dose rate (Figure 2B). Also notable was that none of the dose rates had any effect on the animals’ weight compared with that of the controls (Figure 3). Delivery of the same dose at the lowest rate emerged as being the most effective in inhibiting prostate tumor growth among the 4 tested rates.

Discussion

The results of this study demonstrated that the lowest delivery rate of the same dose of radiation had an inverse effect on tumor volume. Specifically, inhibition of the tumor growth increased as the radiation rate gradually decreased from 14 Gy/min to 0.6 Gy/min. The tumor volumes were significantly reduced compared to no-radiotherapy at lower radiation
rates (Figure 1A and 2A). Furthermore, the radiation rate of 0.6 Gy/min had the strongest effect on tumor volume compared with the higher dose rates of 2, 4, and 14 Gy/min in the PC-3 tumors (Figure 1B and Table 1).

A vast proportion of the published data on the effect of dose rate of radiation was done in vitro. In agreement with our in vivo results, the in vitro studies by Słosarek et al demonstrated that a lower dose rate induced more micronuclei and apoptosis in human melanoma, lung adenocarcinoma, colon cancer, and normal bronchial epithelial cells compared to higher dose rates. In contrast, however, several studies demonstrated that decreased dose rates enhanced the survival of radiated cells, while others found no differences in the survival of diverse cancer cells within a similar dose rate range.

To date, radical prostatectomy (the main option) and external beam radiotherapy remain the most ubiquitous treatments for localized prostate cancer. Standard radiation has been among the most time-consuming radiation treatments for that malignancy, that is, 38 to 45 daily treatments of 1.8 to 2.5 Gy at a rate of 3 to 6 Gy/min for a total treatment duration of 2 months. This treatment protocol is long, costly, and inconvenient. Recent studies showing that prostate cancer cells had an effective response to higher daily radiation doses motivated the transition from the conventional fractionation to hypofractionation, which is defined as the delivery of higher daily doses of radiation over a shorter number of days. This schedule would reduce costs and health care burden, and possibly also make treatment more accessible to patients who do not live near a treatment facility.
This advanced technology of hypofractionation affects the total dose and the dose per fraction without altering the radiation dose rate. Although our results do not support advantages with regard to hypofractionation, treatment costs, and patient inconvenience, we consider that the favorable treatment outcome outweighs the absence of those benefits. Our results in prostate cancer models are consistent with an "inverse dose rate effect" according to which some mammalian cell populations exhibit a marked increase in cell death under low dose exposure. The main theory for explaining this phenomenon is that low dose rates cause a failure to arrest in G2.18

The current work reveals that the radiation delivery dose rate as being a new factor that warrants in-depth study. It will be interesting to further explore our model using other cancer cells and even lower radiation delivery dose rates, as well as seeking the explanation for why the delivery of the same amount of radiation at a very low rate is more effective than at higher delivery rates.

**Conclusions**

Our results indicate that the delivery of radiation at a low dose rate, such as 0.6 Gy/min, is feasible by means of modern linear accelerators, and that it is more effective in inhibiting prostate cancer growth compared to the tested higher dose rates.

**Authors’ Note**

All procedures were done in compliance with the Tel Aviv Sourasky Medical Center Animal Care and Use Committee (permission number 11-6-17).

**Acknowledgment**

The authors would like to thank Hila Granot for her technical support in radiating the mice by the TrueBeam linear accelerator and to Ms. Esther Eshkol for editorial assistance.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received funding through the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF).

**ORCID iD**

Sharon Amir https://orcid.org/0000-0002-1692-3593

**References**

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin [Internet]. 2007;57(1):43-66. http://doi.wiley.com/10.3322/canjclin.57.1.43

2. Von Eyben FE, Kiljunen T, Kangasmaki A, Kairemo K, Von Eyben R, Joensuu T. Radiotherapy boost for the dominant intra-prostatic cancer lesion—A systematic review and meta-analysis. Clin Genitourin Cancer. 2016;14(3):189-197.

3. Shioyama Y, Tsuji H, Suefuji H, et al. Particle radiotherapy for prostate cancer. Int J Urol. 2015;22(1):33-39.

4. Hall EJ, Brenner DJ. The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21(6):1403-1414.
5. Widel M, Przybyszewski WM. Inverse dose-rate effect for the induction of micronuclei in Lewis lung carcinoma after exposure to cobalt-60 gamma rays. Radiat Res [Internet]. 1998;149(1):98-102. http://www.ncbi.nlm.nih.gov/pubmed/9421159

6. Mitchell C, Folkard M, Joiner M. Effects of exposure to low-dose-rate 60Co gamma rays on human tumor cells in vitro. Radiat Res [Internet]. 2002;158(3):311-318. http://www.rrjournal.org/doi/pdf/10.1667/0033-7587(2002)158%5B0311%3AEOETLD%5D2.0.CO;2

7. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med [Internet]. 2007;48(10):1683-1691. http://jnm.snmjournals.org/cgi/doi/10.2967/jnumed.105.028183

8. Chen H, Bao Y, Yu L, Jia R, Cheng W, Shao C. Comparison of cellular damage response to low-dose-rate 125I seed irradiation and high-dose-rate gamma irradiation in human lung cancer cells. Brachytherapy. 2012;11(2):149-156.

9. Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, et al. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim (NY). 2013;42(6):217-224.

10. Ślosarek K, Konopacka M, Rogoliński J, Łatocha M, Sochanik A. Effect of depth on radiation-induced cell damage in a water phantom. Reports Pract Oncol Radiother. 2005;10(1):37-41.

11. Ślosarek K, Konopacka M, Rogolinski J, Sochanik A. Effect of dose-rate and irradiation geometry on the biological response of normal cells and cancer cells under radiotherapeutic conditions. Mutat Res - Genet Toxicol Environ Mutagen. 2014;773:14-22.

12. Wang Z, Zhao Z, Lu J, et al. A comparison of the biological effects of 125I seeds continuous low-dose-rate radiation and 60co high-dose-rate gamma radiation on non-small cell lung cancer cells. PLoS One. 2015;10(8):e0133728.

13. Canazza A, De Grazia U, Fumagalli L, et al. In vitro effects of Cyberknife-driven intermittent irradiation on glioblastoma cell lines. Neurol Sci. 2011;32(4):579-588.

14. Keall PJ, Chang M, Benedict S, Thames H, Vedam SS, Lin PS. Investigating the temporal effects of respiratory-gated and intensity-modulated radiotherapy treatment delivery on in vitro survival: An experimental and theoretical study. Int J Radiat Oncol Biol Phys. 2008;71(5):1547-1552.

15. Sørensen BS, Vestergaard A, Overgaard J, Præstegaard LH. Dependence of cell survival on instantaneous dose rate of a linear accelerator. Radiother Oncol. 2011;101(1):223-225.

16. Verbakel WFAR, Van Den Berg J, Slotman BJ, Sminia P. Comparable cell survival between high dose rate flattening filter free and conventional dose rate irradiation. Acta Oncol (Madr). 2013;52(3):652-657.

17. Lee WR. Prostate cancer and the hypofractionation hypothesis. J Clin Oncol. 2013;31(31):3849-3851.

18. Matsuya Y, McMahon SJ, Tsutsumi K, et al. Investigation of dose-rate effects and cell-cycle distribution under protracted exposure to ionizing radiation for various dose-rates. Sci Rep. 2018;8(1):8287.